{
  "id": 17162543,
  "title": "Aspen Neuroscience prices IPO at $15 per share on Nasdaq",
  "url": "https://urgent.news/2026/10/30/aspen-neuroscience-prices-ipo-at-15-per-share-on-nasdaq",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T02:24:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/aspen-neuroscience-prices-ipo-at-15-per-share-on-nasdaq-432SI-4985722"
  },
  "original_language": "en",
  "account": "Aspen Neuroscience, a clinical-stage biotech focused on Parkinson's disease, priced its IPO at $15 per share on Nasdaq, according to a company press release. The biotech plans to sell 9.375 million shares, projecting gross proceeds of around $140.6 million before fees. Aspen has given underwriters the option to buy up to an additional 1.406 million shares at the public offering price within 30 days. The shares are slated to begin trading on the Nasdaq Global Select Market on October 30, 2026, with the offering expected to close on November 2, 2026, pending customary closing conditions. Aspen Neuroscience is led by Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. as joint bookrunners for the IPO. The company's lead product, sasineprocel, is an investigational autologous iPSC-based cell therapy being tested as a single-dose treatment for Parkinson's disease.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M",
        "url": "https://urgent.news/2026/10/30/aspen-neuroscience-lands-141m-ipo-while-bambusa-secures-169m",
        "published": "2026-10-30T06:11:31.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}